Actively Recruiting
Study of Enfortumab Vedotin and Pembrolizumab Combined With Quemliclustat for Treating Advanced or Metastatic Urothelial Cancer
Led by Fred Hutchinson Cancer Center · Updated on 2026-10-22
27
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination treatment involving quemliclustat, enfortumab vedotin, and pembrolizumab for patients with unresectable locally advanced or metastatic urothelial cancer affecting the bladder, renal pelvis, or ureter. This phase IbII trial aims to test the safety, side effects, and best dose of the combination and assess how well it works to treat cancer that has spread beyond the primary site. Enfortumab vedotin is a targeted antibody-drug conjugate, pembrolizumab is an immunotherapy to help the immune system attack cancer, and quemliclustat may stop tumor growth by blocking enzymes needed for cell growth.
CONDITIONS
Brief Title
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Research Team
R
Rosa Nadal Rios, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here